Neurological Wilson's disease studied with magnetic resonance imaging and with positron emission tomography using dopaminergic markers
Identifieur interne : 000A42 ( Istex/Curation ); précédent : 000A41; suivant : 000A43Neurological Wilson's disease studied with magnetic resonance imaging and with positron emission tomography using dopaminergic markers
Auteurs : Westermark [Suède] ; J. Tedroff [Suède] ; K. Thuomas [Suède] ; P. Hartvig [Suède] ; B. L Ngström [Suède] ; Y. Andersson [Suède] ; K. Hörnfeldt [Suède] ; S. Aquilonius [Suède]Source :
- Movement Disorders [ 0885-3185 ] ; 1995-09.
English descriptors
- KwdEn :
Abstract
Four patients with neurological Wilson's disease were investigated using magnetic resonance imaging (MRI) and positron emission tomography (PET). All patients had dystonia as their major clinical manifestation but also had dysarthria and at the presentation of the disease had choreoathetoid movements in at least one limb. A multitracer approach with PET was used to visualize various aspects of dopaminergic function; [11C]‐(+)‐nomifensine (NMF), [11C]raclopride (RAC) and [11C]‐L‐DOPA (one patient). Correlation analysis of RAC and NMF binding as well as putamen/caudate uptake ratios showed corresponding reductions. The patient investigated with [11C]‐L‐DOPA had a normal striatal uptake. Generally, structural changes as shown by MRI corresponded to reductions both in NMF and RAC binding. There was no evident correspondence between PET findings and the severity of clinical symptoms seen in the individual patient. In two patients with discrete neurological impairment at the time of investigation, PET showed serious presynaptic dopaminergic lesions in the putamen. Our data suggest that the striatal degeneration seen in Wilson's disease comprises a complex pathology involving both afferent and efferent projections. The discrete neurological impairment seen in some patients with gross striatal pathology might be due to concomitant lesions in functionally counteracting basal ganglia circuits.
Url:
DOI: 10.1002/mds.870100511
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000A42
Links to Exploration step
ISTEX:B64B3F60CDECED1F6EC59BA5C7DDBB21367614B7Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neurological Wilson's disease studied with magnetic resonance imaging and with positron emission tomography using dopaminergic markers</title><author><name sortKey="Westermark" sort="Westermark" uniqKey="Westermark" last="Westermark">Westermark</name><affiliation wicri:level="1"><mods:affiliation>Departments of Internal Medicine, Uppsala University, Uppsala, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Departments of Internal Medicine, Uppsala University, Uppsala</wicri:regionArea></affiliation></author><author><name sortKey="Tedroff, J" sort="Tedroff, J" uniqKey="Tedroff J" first="J." last="Tedroff">J. Tedroff</name><affiliation wicri:level="1"><mods:affiliation>Departments of Neurology, Uppsala University, Uppsala, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Departments of Neurology, Uppsala University, Uppsala</wicri:regionArea></affiliation></author><author><name sortKey="Thuomas, K" sort="Thuomas, K" uniqKey="Thuomas K" first="K." last="Thuomas">K. Thuomas</name><affiliation wicri:level="1"><mods:affiliation>Departments of Diagnostic Radiology, Uppsala University, Uppsala, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Departments of Diagnostic Radiology, Uppsala University, Uppsala</wicri:regionArea></affiliation></author><author><name sortKey="Hartvig, P" sort="Hartvig, P" uniqKey="Hartvig P" first="P." last="Hartvig">P. Hartvig</name><affiliation wicri:level="1"><mods:affiliation>Departments of Hospital Pharmacy, University Hospital Uppsala, Uppsala University, Uppsala, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Departments of Hospital Pharmacy, University Hospital Uppsala, Uppsala University, Uppsala</wicri:regionArea></affiliation></author><author><name sortKey="L Ngstrom, B" sort="L Ngstrom, B" uniqKey="L Ngstrom B" first="B." last="L Ngström">B. L Ngström</name><affiliation wicri:level="1"><mods:affiliation>Department of Chemistry, Uppsala University, Uppsala, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Chemistry, Uppsala University, Uppsala</wicri:regionArea></affiliation></author><author><name sortKey="Andersson, Y" sort="Andersson, Y" uniqKey="Andersson Y" first="Y." last="Andersson">Y. Andersson</name><affiliation wicri:level="1"><mods:affiliation>Department of Chemistry, Uppsala University, Uppsala, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Chemistry, Uppsala University, Uppsala</wicri:regionArea></affiliation></author><author><name sortKey="Hornfeldt, K" sort="Hornfeldt, K" uniqKey="Hornfeldt K" first="K." last="Hörnfeldt">K. Hörnfeldt</name><affiliation wicri:level="1"><mods:affiliation>Department of Chemistry, Uppsala University, Uppsala, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Chemistry, Uppsala University, Uppsala</wicri:regionArea></affiliation></author><author><name sortKey="Aquilonius, S" sort="Aquilonius, S" uniqKey="Aquilonius S" first="S." last="Aquilonius">S. Aquilonius</name><affiliation wicri:level="1"><mods:affiliation>Departments of Neurology, Uppsala University, Uppsala, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Departments of Neurology, Uppsala University, Uppsala</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B64B3F60CDECED1F6EC59BA5C7DDBB21367614B7</idno><date when="1995" year="1995">1995</date><idno type="doi">10.1002/mds.870100511</idno><idno type="url">https://api.istex.fr/document/B64B3F60CDECED1F6EC59BA5C7DDBB21367614B7/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000A42</idno><idno type="wicri:Area/Istex/Curation">000A42</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Neurological Wilson's disease studied with magnetic resonance imaging and with positron emission tomography using dopaminergic markers</title><author><name sortKey="Westermark" sort="Westermark" uniqKey="Westermark" last="Westermark">Westermark</name><affiliation wicri:level="1"><mods:affiliation>Departments of Internal Medicine, Uppsala University, Uppsala, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Departments of Internal Medicine, Uppsala University, Uppsala</wicri:regionArea></affiliation></author><author><name sortKey="Tedroff, J" sort="Tedroff, J" uniqKey="Tedroff J" first="J." last="Tedroff">J. Tedroff</name><affiliation wicri:level="1"><mods:affiliation>Departments of Neurology, Uppsala University, Uppsala, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Departments of Neurology, Uppsala University, Uppsala</wicri:regionArea></affiliation></author><author><name sortKey="Thuomas, K" sort="Thuomas, K" uniqKey="Thuomas K" first="K." last="Thuomas">K. Thuomas</name><affiliation wicri:level="1"><mods:affiliation>Departments of Diagnostic Radiology, Uppsala University, Uppsala, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Departments of Diagnostic Radiology, Uppsala University, Uppsala</wicri:regionArea></affiliation></author><author><name sortKey="Hartvig, P" sort="Hartvig, P" uniqKey="Hartvig P" first="P." last="Hartvig">P. Hartvig</name><affiliation wicri:level="1"><mods:affiliation>Departments of Hospital Pharmacy, University Hospital Uppsala, Uppsala University, Uppsala, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Departments of Hospital Pharmacy, University Hospital Uppsala, Uppsala University, Uppsala</wicri:regionArea></affiliation></author><author><name sortKey="L Ngstrom, B" sort="L Ngstrom, B" uniqKey="L Ngstrom B" first="B." last="L Ngström">B. L Ngström</name><affiliation wicri:level="1"><mods:affiliation>Department of Chemistry, Uppsala University, Uppsala, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Chemistry, Uppsala University, Uppsala</wicri:regionArea></affiliation></author><author><name sortKey="Andersson, Y" sort="Andersson, Y" uniqKey="Andersson Y" first="Y." last="Andersson">Y. Andersson</name><affiliation wicri:level="1"><mods:affiliation>Department of Chemistry, Uppsala University, Uppsala, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Chemistry, Uppsala University, Uppsala</wicri:regionArea></affiliation></author><author><name sortKey="Hornfeldt, K" sort="Hornfeldt, K" uniqKey="Hornfeldt K" first="K." last="Hörnfeldt">K. Hörnfeldt</name><affiliation wicri:level="1"><mods:affiliation>Department of Chemistry, Uppsala University, Uppsala, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Chemistry, Uppsala University, Uppsala</wicri:regionArea></affiliation></author><author><name sortKey="Aquilonius, S" sort="Aquilonius, S" uniqKey="Aquilonius S" first="S." last="Aquilonius">S. Aquilonius</name><affiliation wicri:level="1"><mods:affiliation>Departments of Neurology, Uppsala University, Uppsala, Sweden</mods:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Departments of Neurology, Uppsala University, Uppsala</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1995-09">1995-09</date><biblScope unit="vol">10</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="596">596</biblScope><biblScope unit="page" to="603">603</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">B64B3F60CDECED1F6EC59BA5C7DDBB21367614B7</idno><idno type="DOI">10.1002/mds.870100511</idno><idno type="ArticleID">MDS870100511</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Magnetic resonance imaging</term><term>Positron emission tomography</term><term>Wilson's disease</term><term>[11C]Raclopride</term><term>[11C]‐(+)‐nomifensine</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Four patients with neurological Wilson's disease were investigated using magnetic resonance imaging (MRI) and positron emission tomography (PET). All patients had dystonia as their major clinical manifestation but also had dysarthria and at the presentation of the disease had choreoathetoid movements in at least one limb. A multitracer approach with PET was used to visualize various aspects of dopaminergic function; [11C]‐(+)‐nomifensine (NMF), [11C]raclopride (RAC) and [11C]‐L‐DOPA (one patient). Correlation analysis of RAC and NMF binding as well as putamen/caudate uptake ratios showed corresponding reductions. The patient investigated with [11C]‐L‐DOPA had a normal striatal uptake. Generally, structural changes as shown by MRI corresponded to reductions both in NMF and RAC binding. There was no evident correspondence between PET findings and the severity of clinical symptoms seen in the individual patient. In two patients with discrete neurological impairment at the time of investigation, PET showed serious presynaptic dopaminergic lesions in the putamen. Our data suggest that the striatal degeneration seen in Wilson's disease comprises a complex pathology involving both afferent and efferent projections. The discrete neurological impairment seen in some patients with gross striatal pathology might be due to concomitant lesions in functionally counteracting basal ganglia circuits.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A42 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000A42 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:B64B3F60CDECED1F6EC59BA5C7DDBB21367614B7
|texte= Neurological Wilson's disease studied with magnetic resonance imaging and with positron emission tomography using dopaminergic markers
}}
| This area was generated with Dilib version V0.6.23. |  |